Next Article in Journal
Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature
Next Article in Special Issue
Macrophage Origin, Metabolic Reprogramming and IL-1β Signaling: Promises and Pitfalls in Lung Cancer
Previous Article in Journal
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients
Previous Article in Special Issue
Circulating Tumor Cell Detection in Lung Cancer: But to What End?
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Cancers 2019, 11(3), 283; https://doi.org/10.3390/cancers11030283

Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?

1
Laboratory of Clinical and Experimental Pathology, Hospital-Integrated Biobank (BB-0033-00025), Nice Hospital University, FHU OncoAge, Université Côte d’Azur, Nice 06000, France
2
Team 4, Institute for Research on Cancer and Aging, Nice (IRCAN), INSERM U1081/UMR CNRS 7284, FHU OncoAge, Université Côte d’Azur, Nice 06107, France
3
Department of Pathology, Hôpital Européen Georges Pompidou, APHP, Paris 75015, France
4
INSERM U970, Université Paris Descartes Sorbonne Paris-Cité, Paris 75015, France
5
Department EMEA, Indica Labs, 2469 Corrales Rd Bldg. A-3 Corrales, NM 87048, USA
6
Department of Immunology, Hôpital Européen Georges Pompidou, Paris 75015, France
*
Author to whom correspondence should be addressed.
Received: 30 January 2019 / Revised: 23 February 2019 / Accepted: 25 February 2019 / Published: 27 February 2019
Full-Text   |   PDF [8621 KB, uploaded 27 February 2019]   |  

Abstract

As targeted molecular therapies and immuno-oncology have become pivotal in the management of patients with lung cancer, the essential requirement for high throughput analyses and clinical validation of biomarkers has become even more intense, with response rates maintained in the 20%–30% range. Moreover, the list of treatment alternatives, including combination therapies, is rapidly evolving. The molecular profiling and specific tumor-associated immune contexture may be predictive of response or resistance to these therapeutic strategies. Multiplexed immunohistochemistry is an effective and proficient approach to simultaneously identify specific proteins or molecular abnormalities, to determine the spatial distribution and activation state of immune cells, as well as the presence of immunoactive molecular expression. This method is highly advantageous for investigating immune evasion mechanisms and discovering potential biomarkers to assess mechanisms of action and to predict response to a given treatment. This review provides views on the current technological status and evidence for clinical applications of multiplexing and how it could be applied to optimize clinical management of patients with lung cancer. View Full-Text
Keywords: multiplexed; brightfield; chromogenic; fluorescence; molecular; immune profiling; immune-oncology; digital; lung cancer multiplexed; brightfield; chromogenic; fluorescence; molecular; immune profiling; immune-oncology; digital; lung cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Hofman, P.; Badoual, C.; Henderson, F.; Berland, L.; Hamila, M.; Long-Mira, E.; Lassalle, S.; Roussel, H.; Hofman, V.; Tartour, E.; Ilié, M. Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time? Cancers 2019, 11, 283.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top